NCT03100318已完成3 期
Benzbromarone-Controlled, Double-Blind, Comparative Study of FYU-981 for Hyperuricemia With or Without Gout to Evaluate the Safety and Noninferiority of FYU-981 (Phase III Study)
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 201
- 试验地点
- 1
- 主要终点
- Percent reduction from baseline in serum urate level at the final visit
研究概览
简要总结
FYU-981 or Benzbromarone are administrated to hyperuricemia patients with or without gout for 14 weeks to compare the efficacy and safety of these drugs by the method of multicenter, randomized, double-blind, ascending dose regimen.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Hyperuricemic or gout patients
- •Serum urate level:
- •>= 7.0mg/dL in patients with history of gout, or >= 8.0mg/dL in patients with hypertension, diabetes or metabolic syndrome, or >= 9.0mg/dL
排除标准
- •Gouty arthritis within two weeks before start of study treatment
- •Secondary hyperuricemia
- •HbA1c: >= 8.4%
- •Uric acid-overproduction type in the classification of hyperuricemia
- •History of, clinically significant cardiac, hematologic and hepatic disease
- •Kidney calculi or clinically significant urinary calculi
- •Hepatic dysfuction, or AST: >=100 IU/L or ALT: >=100 IU/L at the pre-examination
- •eGFR: < 30mL/min/1.73m^2
- •Systolic blood pressure: >= 180 mmHg
- •Diastolic blood pressure: >= 110 mmHg
研究组 & 干预措施
FYU-981
Experimental
干预措施: FYU-981 (Drug)
Benzbromarone
Active Comparator
干预措施: Benzbromarone (Drug)
结局指标
主要结局
Percent reduction from baseline in serum urate level at the final visit
时间窗: 14 weeks
Percent reduction from baseline in serum urate level at the final visit
次要结局
未报告次要终点
研究者
研究点 (1)
Loading locations...
相似试验
已完成
3 期
Febuxostat-Controlled, Double-Blind, Comparative Study of FYU-981 in Hyperuricemia With or Without GoutHyperuricemia With or Without GoutNCT03372200Mochida Pharmaceutical Company, Ltd.203
已完成
2 期
Study of FYU-981 in Hyperuricemia With or Without GoutHyperuricemiaNCT02416167Fuji Yakuhin Co., Ltd.200
已完成
2 期
Study of FYU-981 in Hyperuricemia With or Without GoutHyperuricemiaNCT02344862Fuji Yakuhin Co., Ltd.80
尚未招募
2 期
Effect of Unani medicine in joint paiCTRI/2022/04/042162ational Institute of Unani Medicine
未知
3 期
Efficacy and safety of FYX-051 in hyperuricemic patients with moderate renal insufficiencyHyperuricemia and GoutJPRN-jRCT2080221136SANWA KAGAKU KENKYUSHO Co., Ltd.